Whole genome sequencing: Genomic sequencing and molecular diagnostic results
Whole exome sequencing: Genomic sequencing and molecular diagnostic results
Study summary
This study will seek to determine if whole genome sequencing (WGS) improves diagnostic rates, and outcomes for congenital diarrhea and enteropathy (CODE) patients. The investigator will enroll 180 patients in a randomized controlled study to either WGS or whole exome sequencing (WES). This study is designed to evaluate whether CODE patients would benefit from WGS guided precision medicine.
Eligibility
Sex
ALL
Min age
—
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients with chronic diarrhea lasting greater than 2 months
* Patients with consent from parents or legal guardians
* Biological relative of a patient enrolled in this study.
Exclusion Criteria:
* Chronic diarrhea caused by specific infections, i.e. CMV, Clostridioides difficile
* Chronic diarrhea with necrotizing enterocolitis, short bowel syndrome
* Functional diarrhea
* Patients with previously confirmed monogenic diarrhea
* Patients with poor compliance
Primary outcome measure(s)
Diagnostic rates between WGS and WES — Within approximately 60 days of enrollment Diagnostic rate of genome and exome based on rate of clinically confirmed diagnoses.
Trial sites (1)
Facility
City
Region
Status
Ying Huang
Shanghai
Shanghai Municipality
Recruiting
More Children's Hospital of Fudan University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.